Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for SIBO in HFpEF
NCT06652087Recruiting
- Sponsor
- Sechenov First Moscow State Medical University
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rifaximin in small intestinal bacterial overgrowth (SIBO) (2 arms), sponsored by Sechenov First Moscow State Medical University. Primary endpoints: Change in the functional class of chronic heart failure at Day 40 and Change in clinical condition at Day 40. Started Sep 2024; status: recruiting.
02
Drugs
rifaximin
03
Conditions
small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT06652087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652087.